By integrating digital tools like ePRO, we can bridge the gap between patients’ lived experiences and clinical research.
Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy radiotherapy. The study demonstrated an improvement in 3-year freedom from ...
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced ...
As part of our commitment, we've once again partnered with Statista, Inc. to evaluate the implementation of Patient Reported ...
The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...
The first randomized trial to compare photon- and proton-based radiation therapy for breast cancer finds that patients report ...
According to a meta-analysis, patients’ baseline quality of life, functional scores, and symptom burden all predict cancer survival.
Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...
A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in ...
Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Patients with locally advanced ...
Certain patient-reported outcomes (PROs) can predict overall survival (OS) in patients with cancer, according to research published in JAMA Oncology. Researchers found that higher baseline scores in ...
In children receiving peanut oral immunotherapy, adverse event rates can be predicted from characteristics like large skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback